Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Retrophin's Focus Shifts After Phase III PKAN Drug's Failure

Executive Summary

Fosmetpantotenate missed all endpoints in a Phase III trial, so Retrophin will shelve the candidate for the rare disease PKAN. Now, the biotech turns focus to Phase III sparsentan in a pair of indications.

You may also be interested in...



BridgeBio-Backed CoA Therapeutics Challenges Retrophin In Genetic Disorder PKAN

Emerging Company Profile: CoA Therapeutics plans to start a Phase I study of a CoA modulator in the rare, genetic disorder PKAN during the first quarter of 2020.

Life's A Musical For Martin Shkreli

The absurdity that's surrounded former drug company CEO Martin Shkreli, who has been indicted on eight federal charges, including securities fraud, has been made into a New York musical – really!

FDA refuses investigator trials of PKAN drug; Retrophin hit

Shares of Retrophin plummeted almost 20% on 14 April after the company revealed the FDA is refusing to clear investigational new drug applications (INDs) for investigator-sponsored trials of RE-024, an phosphopantothenate replacement therapy, for pantothenate kinase-associated neurodegeneration (PKAN), a rare and life-threatening neurological disorder.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125750

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel